MTOR and cancer: Taken together, the feedback activation of the STAT3 signaling pathway in PTEN-deficient cancer cells limits the therapeutic efficiency of PI3K/mTOR inhibitors, which can be circumvented by targeting the PI3K and STAT3 pathways simultaneously.